Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

3
Is WisdomTree International High Dividend Fund (DTH) a Hot ETF Right Now?

12h zacks
Launched on 06/16/2006, the WisdomTree International High Dividend Fund (DTH - Free Report) is a smart beta exchange traded fund offering broad exposure to the Broad Developed World ETFs category of the market.
0941 BP CHLKF CHL BP BPAQF EFA BP.A BP.B IEFA

36
Is WisdomTree International High Dividend Fund (DTH) a Hot ETF Right Now?

2018-06-22 zacks
Making its debut on 06/16/2006, smart beta exchange traded fund WisdomTree International High Dividend Fund (DTH - Free Report) provides investors broad exposure to the Broad Developed World ETFs category of the U.S. equity market.
FP BP BP BPAQF EFA BP.A BP.B IEFA

33
What Sectors And Stocks Have ETFs Been Buying?

2018-06-08 seekingalpha
Gold-backed ETF holdings added 72.2 tons to 2,481 tons in April which is the strongest month of net inflows in more than a year.
MAT IVV TRV HAS CINF IVV IEFA

35
Is SPDR MSCI EAFE StrategicFactors ETF (QEFA) a Hot ETF Right Now?

2018-05-28 zacks
The SPDR MSCI EAFE StrategicFactors ETF (QEFA - Free Report) was launched on 06/04/2014, and is a smart beta exchange traded fund designed to offer broad exposure to the Broad Developed World ETFs category of the U.S. equity market.
DUKH AZN DUK EFA IEFA

29
Is WisdomTree International Hedged Quality Dividend Growth Fund (IHDG) a Hot ETF Right Now?

2018-05-16 zacks
Making its debut on 05/07/2014, smart beta exchange traded fund WisdomTree International Hedged Quality Dividend Growth Fund (IHDG - Free Report) provides investors broad exposure to the Broad Developed World ETFs category of the U.S. equity market.
HD RHHVF UL UN UNLYF ULVR RHHBY EFA UNLNF IEFA RHHBF

21
ETF Asset Report for April 2018: Bonds Top

2018-04-30 zacks
The month of April was mixed with earnings showing promise and broader markets returning decent returns despite rising yields and trade tensions. Oil has been on an uptrend. Overall, SPDR S&P 500 ETF (SPY - Free Report) gained about 3.5% in a month’s time (as of Apr 27, 2018), SPDR Dow Jones Industrial Average ETF (DIA - Free Report) rose 2.9% while Nasdaq-100-bsed ETF PowerShares QQQ ETF (QQQ - Free Report) jumped 4.
AGG IVV IEMG DIA SPY IVV EFA FLOT SHY IEFA

109
U.S. Weekly FundFlows Insight Report: Fund Flows Remain Positive For The Week In Spite Of Market Declines And Rising Yields

2018-04-27 seekingalpha
For the second week in three, investors were net purchasers of fund assets (including those of conventional funds and ETFs), injecting a little more than $8.0 billion. In spite of market declines and rising yields, fund investors were net purchasers of equity funds (+$3.5 billion), money market funds (+$3.3 billion), taxable bond funds (+$0.9 billion), and municipal bond funds (+$229 million) for the fund flows week ended April 25, 2018.
IVV QQQ CAT IEMG VZ IVV UTX BA IWM IEFA

37
Q1 ETF Inflows Dive at BlackRock: Tough Road Ahead?

2018-04-13 zacks
Unlike preceding quarters,net asset inflows to BlackRock Inc.’s (BLK - Free Report) ETF business dropped 46% in the first quarter to $34.6 billion from the year-ago quarter. However, despite a decline in inflows, BlackRock’s first-quarter 2018 adjusted earnings came in at $6.70 per share, which breezed past the Zacks Consensus Estimate of $6.42.
GD BLK SIG IWD IEMG EFA IEFA EEM SIG

8
Winning ETF Areas of March

2018-04-02 zacks
The month of March was all about the Fed rate hike, trade war fears, the tech market crash and a moderation in Treasury bond yields. Let’s see how investors reacted to this situation and where they parked their money in the month. The data are as of etf.com (as of March 29, 2018) (read: ETF Asset Report for First Quarter of 2017).
VEA O87 IEMG GDX EFA FDN GLD IWM IEFA

8
Wining ETF Areas of March

2018-04-02 zacks
The month of March was all about the Fed rate hike, trade war fears, the tech market crash and a moderation in Treasury bond yields. Let’s see how investors reacted to this situation and where they parked their money in the month. The data are as of etf.com (as of March 29, 2018) (read: ETF Asset Report for First Quarter of 2017).
VEA O87 IEMG GDX EFA FDN GLD IWM IEFA

7
Q1 ETF Asset Report: Developed Markets Win, High-Yield Loses

2018-03-29 zacks
The markets were more tensed than relaxed in the first quarter of 2018. Increasing inflationary expectations and rising rate fears pushed up bond yields and spurred equity sell-offs in late January and early February. Then, Trump-induced trade fear (thanks to his announcement of import tariffs) and a tech rout in March did the rest of the damage (read: 5 Reason Why FANG ETFs Lost Their Charm in March).
VEA VOO IEMG SPY EFA IEFA EEM

29
ETF Month #4: Developed Markets (Ex-North America) With EFA. But Is There A Better Alternative?

2018-03-18 seekingalpha
During "ETF Month", I plan to survey a number of ETFs that have a lot of followers on Seeking Alpha, but for some reason don't have much coverage on the site. Hopefully, this will improve the visibility of Cambridge Income Laboratory and draw more members to our service, allowing me to make the newsletter better than ever. I will also be taking ETF suggestions, so do let me know if you have any ETFs on your horizon.
VEA RDS.B RDS.A IEMG BATS RDSB 4162 RDSA EFA RYDBF NVS RYDAF EEM IEFA

0
U.S. Weekly FundFlows Insight Report: Equity Funds Attract Net New Money For The Week In Spite Of Fears Of Inflation And A Trade War

2018-03-16 seekingalpha
For the first week in four, investors were net redeemers of fund assets (including those of conventional funds and ETFs), withdrawing $291 million. However, the headline number was a bit misleading. While fund investors were net redeemers of money market funds (-$24.2 billion), they padded the coffers of equity funds (+$20.4 billion), taxable bond funds (+$3.2 million), and municipal bond funds (+$339 million) for the fund flows week ended March 14, 2018.
QQQ SHV EZU IEFA

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 46432F842